Cardiovascular disease
Drug research and approvals for cardiovascular disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 8,110 studies of cardiovascular disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 53 drug trials for it since 2013, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 8,110
- Trials authorized in Canada: 53
- FDA orphan approvals: 0
- EU medicines: 4
Recruiting Now
Newest start dates first, of 8,110 recruiting on ClinicalTrials.gov ↗- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment…NCT06948084 · Phase 2 · National Cancer Institute (NCI) · starts May 22, 2027
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment…NCT07463807 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Apr 12, 2027
- Exercise Induced Hypoalgesia in Pain-free Stroke and Healthy Populations: a Cohort StudyNCT07327593 · Not applicable · Neuron, Spain · starts Apr 1, 2027
- AlEX-DHF: Ablation and Exercise in Diastolic Heart FailureNCT06650995 · Not applicable · Technical University of Munich · starts Feb 1, 2027
- Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung…NCT07761910 · Phase 2 · Indiana University · starts Jan 1, 2027
- Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid…NCT06714097 · Not applicable · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · starts Jan 1, 2027
- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,…NCT07083557 · Not reported · Bettina Mittendorfer · starts Jan 1, 2027
- Ask Questions About Clinical TrialsNCT07343297 · Not applicable · Barbara Ann Karmanos Cancer Institute · starts Dec 30, 2026
- Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)NCT07169799 · Not applicable · Mayo Clinic · starts Dec 22, 2026
Trials Authorized in Canada
The 10 newest of 53; search them all in Canada trials| Aug 20, 2026 | A phase III, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…PETRELINTIDE (RO7895515) | Roche | Pending |
| Aug 6, 2026 | Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either…ZENAGAMTIDE INJECTION | Novo Nordisk | Ongoing |
| Sep 22, 2025 | Zenith: a phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zilebesiran in addition to standard of care…ZILEBESIRAN (ALN-AGT01) | Alnylam Pharmaceuticals | Ongoing |
| Sep 22, 2025 | A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of orforglipron on the incidence of major adverse…ORFORGLIPRON (LY3502970) | Eli Lilly | Ongoing |
| Jul 22, 2025 | A phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of muvalaplin on the reduction of major adverse cardiovascular events…MUVALAPLIN (LY3473329) | Eli Lilly | Ongoing |
| Jun 26, 2025 | A phase 3 randomized, double-blind, placebo-controlled study to evaluate the impact of maridebart cafraglutide on cardiovascular outcomes in participants with…MARIDEBART CAFRAGLUTIDE (AMG 133) | Amgen | Ongoing |
| Jun 13, 2025 | A phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (bi 690517) and…VICADROSTAT (BI 690517) / EMPAGLIFLOZIN (BI 10773) | Boehringer Ingelheim Pharmaceuticals, Inc. | Ongoing |
| Jun 12, 2025 | A single arm, multicenter, open-label extension (ole) trial to evaluate long-term safety and tolerability of pelacarsen (tqj230) in participants who completed…PELACARSEN (TQJ230) | Novartis Pharmaceuticals Corporation | Ongoing |
| Jun 5, 2025 | A double-blind, randomized, placebo-controlled, multi-center study evaluating the safety, tolerability, and effect of olpasiran on coronary artery plaque…OLPASIRAN (AMG 890) | Amgen | Ongoing |
| May 16, 2025 | A phase III, randomized, double-blind, placebo-controlled, parallel-group study to assess the effect of azd0780 on major adverse cardiovascular events in…LAROPROVSTAT (AZD0780) | AstraZeneca Pharmaceuticals LP | Ongoing |
Medicines Authorised in the EU
Newest first| Sep 29, 2010 | Telmisartan Actavistelmisartan · generic | Actavis Group PTC ehf | EMA ↗ |
| Jun 4, 2010 | Toluratelmisartan · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Dec 16, 1998 | Micardistelmisartan | Boehringer Ingelheim International GmbH | EMA ↗ |
| May 17, 1998 | Optisonperflutren | GE Healthcare AS | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA